MindRank Therapeutics Participates in BiG MomenT Seminar, Showcasing AI-Driven Drug Design Innovations

Recently, the BiG MomenT Seminar, a small high-end forum hosted by BiG Biotech Innovation Society, was successfully held in Shanghai. This forum, themed "AI Meets Life Science," brought together top experts and industry leaders from the fields of life science and artificial intelligence.MindRank Founder and CEO Zhangming Niu Invited to Panel Discussion, Engaging in In-depth Exchange on AI-empowered Drug Design with Founders from Tencia Pharmaceuticals, Pylon Bio, and Huashen Intelligent Medicine.

Amid the powerful global wave of AI technology, the life sciences field is undergoing profound transformations. AI not only accelerates the drug discovery process but also demonstrates immense potential in areas such as enzyme and protein directed design, driving the industry into an intelligent development phase. This BiG MomenT Seminar, adhering to the concept of gathering elites and fostering in-depth exchanges, invites thought leaders and representatives from emerging companies in the fields of AI-driven drug design and AI-based enzyme and protein design to explore cutting-edge technological trends, industry pain points, and potential opportunities, facilitating intellectual exchange and consensus building.

During the roundtable discussion, Niu Zhangming, founder and CEO of MindRank, shared practical experiences and insights on how AI facilitates new drug development. Drawing from the company’s self-developed industrial-grade AI pharmaceutical platform and its pipeline of innovative drugs under research, the AI platform leverages top-tier AI algorithm models and integrates a profound understanding of biological mechanisms. This enables precise drug design and optimization, systematically enhancing the efficiency and success rate of new drug development.

Currently, MindRank is steadily advancing a series of new drug pipelines with the potential for first-in-class or best-in-class, covering disease areas such as oncology and metabolism.The first self-developed GLP-1RA small molecule oral drug MDR-001 has successfully entered Phase IIb clinical research.At the same time, the company has recently launchedAI-empowered rational design platform for molecular glues and ADME/T property prediction platform software,To further promote the intelligence and efficiency of drug research and development, and to help achieve more innovative breakthroughs in the life and health field.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was included in Fortune magazine's IMPACT list as one of "China's most socially impactful entrepreneurial companies."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai